Sandoz is the first company to receive approval of a biosimilar in the US through the new FDA biosimilars pathway established under BPCIA Zarxio is approved for all indications included in the ...

Peg-filgrastim is a form of G-CSF with a sustained duration of action due to self-limited clearance. We administered 6 mg peg-filgrastim to 18 autograft recipients on day +1 after transplantation for ...

The digital press release with multimedia content can be accessed here: Holzkirchen, September 3, 2015 - Sandoz, a Novartis company, announced today that Zarxio(TM) (filgrastim-sndz) is now available ...

Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade ...

PURPOSE: This multicenter, randomized, double-blind, active-control study was designed to determine whether a single subcutaneous injection of pegfilgrastim (SD/01, sustained-duration filgrastim; 100 ...

This was a randomized, open-label trial of three schedules of myeloid growth factors administered after MC for the collection of CD34 + PBSC. The MC regimen – cyclophosphamide and etoposide (CE) or ...

Novartis’ (NVS) generic arm, Sandoz, announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recommended the approval of its biosimilar version of ...

- Nivestim(TM), Hospira's filgrastim, has received approval from the European Commission (EC) for the prevention of febrile neutropenia (FN) and reduction in duration of chemotherapy-induced ...

A biosimilar version of filgrastim (EP2006, Sandoz/Novartis) has today been recommended for approval in the United States. The new product is like a generic version of the brand-name filgrastim, ...

Holzkirchen, March 6, 2015-Sandoz, a Novartis company, announced today that the US Food and Drug Administration (FDA) approved Zarxio(TM) (filgrastim-sndz) for all indications included in the ...

The digital press release with multimedia content can be accessed here: Holzkirchen, September 3, 2015-Sandoz, a Novartis company, announced today that Zarxio(TM) (filgrastim-sndz) is now available in ...